Israel Innovation Authority רשות החדשנות
Shosh Merchav, PhD., MBA, serves as a Life Sciences Evaluator at the Israel Innovation Authority since December 2014 and is the CEO of Multifacet BioSolutions Ltd. since February 2013, specializing in early-stage project development in the biotech sector. Previous roles include Director of Oncology and Cell Therapy Projects at Teva Innovative Ventures and Senior Manager for Oncology Projects at Teva Global Branded Products. Additionally, Shosh Merchav held the position of General Manager and Director of Research and Operations at ViaCell Singapore, where the R&D subsidiary was initiated. A former Senior Lecturer and Head of the Hematopoiesis Unit at Technion - Israel Institute of Technology, Shosh Merchav has contributed significantly to the field with over 35 peer-reviewed publications. Educational credentials include a PhD in Medical Sciences from Erasmus University Rotterdam and an MBA from the University of Haifa.
Israel Innovation Authority רשות החדשנות
The Israel Innovation Authority is Israel's central agency to manage the country’s governmental support of the resource of innovation. As the governments' operational arm in the arena of technological innovation and R&D, the goal of the Authority is to provide professional support and infrastructure to government efforts to encourage innovation in all industry sectors, complementing the major role that Israel already plays in the global high-tech sector. The Israel Innovation Authority has three main roles: creating infrastructure to support diverse industries, developing tools and programs that suit the needs of the industry, and budgeting and financing high-risk projects and products. In addition to these roles, the Authority serves as a central hub for knowledge and consists of six customer-oriented “Innovation Divisions,” each providing a variety of tools for each market segment and stage in the life cycle of a product: Technological Infrastructure, Advanced Manufacturing, International Collaborations, Societal Challenges, Growth and Early Stage.